Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132085 | 0.82 | SMN1; SMN2 (0.65) | SMN1; SMN2EPHX1HDAC3HDAC1HDAC2 | |
| SCHEMBL10132039 | 0.82 | ALDH1A1 (0.52) | SMN1; SMN2HDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL25919001 | 0.79 | EPHX1 (0.64) | SMN1; SMN2EPHX1HDAC3HDAC1HDAC2 | |
| SCHEMBL7543330 | 0.78 | GNAI3 (0.53) | EPHX1ALDH1A1CASP2EPHX2 | |
| SCHEMBL18893060 | 0.77 | GNAI3 (0.76) | EPHX1CASP2EPHX2 | |
| SCHEMBL5997943 | 0.77 | HDAC3 (0.67) | SMN1; SMN2EPHX1HDAC3HDAC1HDAC2 | |
| SCHEMBL21842319 | 0.75 | SMN1; SMN2 (0.68) | SMN1; SMN2EPHX1HDAC3HDAC1HDAC2 | |
| SCHEMBL13708632 | 0.75 | SMN1; SMN2 (0.69) | SMN1; SMN2EPHX1HDAC3HDAC1HDAC2 | |
| SCHEMBL4455867 | 0.75 | SMN1; SMN2 (0.69) | SMN1; SMN2EPHX1HDAC3HDAC1HDAC2 | |
| SCHEMBL23975362 | 0.74 | SMN1; SMN2 (0.66) | SMN1; SMN2EPHX1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101186-B2 | Peptides that block the binding of IgG to FcRn | SYNTONIX PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | SMN1; SMN2 4722/4885EPHX1 3281/4885HDAC3 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.